Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11800602 | 0.93 | MAPT (0.51) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL23735965 | 0.91 | MAPT (0.50) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL22110976 | 0.91 | MAPT (0.50) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL22328919 | 0.91 | MAPT (0.50) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL11339768 | 0.90 | USP2 (0.51) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL21174509 | 0.87 | MAPT (0.50) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL8806385 | 0.86 | PKM (0.53) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL8342486 | 0.86 | ALDH1A1 (0.60) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL14761847 | 0.85 | ALDH1A1 (0.52) | MAPTPKMPOLBNPC1RAB9A | |
| SCHEMBL14944103 | 0.84 | POLB (0.53) | MAPTPKMPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8193357-B2 | Androgen receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | MAPT 4308/4885PKM 2968/4885POLB 3139/4885 |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | MAPT 4308/4885PKM 2968/4885POLB 3139/4885 |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | MAPT 4308/4885PKM 2968/4885POLB 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.